The Carnitine PromiseWhat is Carnitine and DoxorubicinThe Story Behind the PromiseThe Clinical Study and Your PhysicianCarnitine's Broad Health Benefits
The Carnitine Promise in Greater DetailLinks to Other ResourcesAbout Dr. Stephen L. Defelice, M.D.


This section contains two parts primarily providing information for your doctor. They are as follows:

Carnitine-Cancer Summary

Carnitine-Doxorubicin Clinical Study for the Treatment of Stages III-IV Ovarian Cancer
There is a summary written by Dr. DeFelice describing how the carnitine-doxorubicin story began as well as a description of selected publications which support the potential clinical effectiveness and safety of carnitine. It also contains a description of the clinical protocal.
READ>


Highlights

The Carnitine-Doxorubicin Promise for the Treatment of Ovarian Cancer
READ>


Enclosures

This section contains the results of selected published scientific studies either as complete publications, abstracts, or summaries either directly or indirectly, supporting the potential of carnitine-doxorubicin for the treatment of cancer in general.

The clinical design of the study is included as well as the FDA approved package inserts of both oral and intravenous carnitine.

Items linked below will download as .pdf files which can be viewed and printed in Mac Preview or Acrobat Reader.

1. A review of carnitine’s clinical cardiovascular profile by Dr. Carl J. Pepine entitled, “The Therapeutic Potential of Carnitine in Cardiovascular Disorders.” Though it was published in 1991, and more positive clinical studies have followed since then, this review covers carnitine’s broad clinical potential including doxorubicin cardiotoxicity.
READ>

2. Chinese hamster ovarian culture cell abstract.
READ>

3. Vanderbilt Human ovarian cancer culture study.
READ>

4. Fatty acid proposed mechanism of action — the human colon cancer cells.
READ>

5. Mitochondrion and death ligand proposed mechanism of action — mouse hepatic cancer cells.
READ>

6. Chronic preclinical studies demonstrating carnitine’s ability to block doxorubicin’s toxicity.
READ ITEM 1> READ ITEM 2>   READ ITEM 3>

7. Clinical study on patients with non-Hodgkin’s lymphoma demonstrating that carnitine block’s doxorubicin’s cardiotoxicity as well as corrects doxorubicin-induced mitochondrial toxicity.
READ>

8. Acetylcarnitine-mitoxantrone.
READ>

9. Proprionylcarnitine-taxol
READ>

10. Low carnitine levels in adult and pediatric cancer patients.
READ>

11. Examples of carnitine’s broad anti toxic activity are AZT, methotrexate, carboplatinum, formaldehyde and diphtheria toxin.
READ ITEM 1>   READ ITEM 2>   READ ITEM 3>   READ ITEM 4>   READ ITEM 5>
READ ITEM 6>

12. Protocol of the clinical study.
READ >

13. Carnitine package inserts, Sigma tau-Carnitor, for the intravenous and oral forms.
READ>

Warning: All three Carnitines are available as dietary supplements in commercial outlets and should only be taken for a serious medical condition under a physician's supervision.

Next page: In the News